Targeting the immune response to treat Ewing Sarcoma
Official title: Attacking the Immunopeptidome of Ewing Sarcoma
Funded at Stanford University · NIH-10927350 · Data updated 2026-11-12
This study is exploring new treatments for Ewing Sarcoma, a type of bone cancer that mainly affects kids and young adults, by using the immune system to help it recognize and fight the cancer cells more effectively.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 11, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $662,764 |
| NIH project number | 5U01CA281865-02 |
| Project ID | NIH-10927350 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and young adults diagnosed with Ewing Sarcoma, particularly those with metastatic or recurrent disease.
✕Less likely to help
Patients with Ewing Sarcoma who do not express the specific proteins targeted by this research may not benefit from these therapies.
What this research studies
This research investigates new ways to treat Ewing Sarcoma, a type of bone cancer that primarily affects children and young adults. It focuses on harnessing the immune system to recognize and attack cancer cells by identifying specific proteins that are overexpressed in Ewing Sarcoma but not found in healthy tissues. The approach involves using advanced techniques to profile the immune response and develop targeted therapies that can overcome the body's natural tolerance to these proteins. By utilizing immunotherapy, the goal is to improve treatment outcomes for patients with this challenging cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for Ewing Sarcoma, potentially improving survival rates and reducing long-term side effects for patients.
How similar studies have gone: Previous research has shown promise in using immunotherapy approaches for other cancers, but this specific application to Ewing Sarcoma is novel and untested.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Mackall, Crystal — Stanford University
- Study coordinator: Mackall, Crystal
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.